| Name | Title | Contact Details |
|---|
Greeley Place Retirement is a Greeley, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Assisted Living *Skilled Nursing* Short-term rehab* The Benedictine Health System is one of the largest Catholic senior living organizations in the country, operating more than 35 communities in five states. BHS is a mission-based, non-profit health system headquartered in Minnesota, sponsored by the Benedictine Sisters of St. Scholastica Monastery in Duluth. BHS provides complete senior living and care services for aging adults, including independent housing, assisted living, long-term skilled nursing care, short-term rehabilitation and memory care. Mission The Benedictine Health System is a Catholic, faith-based organization entrusted with advancing the life-enhancing senior care ministry of the Benedictine Sisters of Duluth, Minnesota. We witness to God`s love by creating compassionate communities providing support to those we serve to live fully and live well with special concern for the underserved and those in need. Vision Creating Benedictine Living Communities where health, wellness and choice come to life.
Transit Resources Inc is a Livermore, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MERIAL Limited is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. MERIAL Limited is based in Duluth, GA. You can find more information on MERIAL Limited at www.merial.com
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.